1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

 
• By Mary Jo Laffler

Detailed results presented at ACC show a reduction in risk of major adverse cardiovascular events, but perhaps not at the level hoped for by payers.

Cholesterol plaque in artery

As the significance of the level of benefit seen in Amgen Inc.'s FOURIER cardiovascular outcomes trial is debated, the company announced a new rebate program to encourage and support use of its PCSK9 inhibitor Repatha (evolocumab).

Amgen had already announced the overall positive results of FOURIER in February, but the details were not known until its presentation at the American College of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.